Novel CAR T-Cell Therapy Active in Relapsed, Refractory Numerous Myeloma, Cancer Network, The Oncology Journal
Novel CAR T-Cell Therapy Active in Relapsed, Refractory Numerous Myeloma Administration of bb2121, a novel anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy, produced anti-tumor responses in intensely pretreated patients with relapsed/refractory numerous myeloma, according to interim data from an on-going phase I clinical trial.